Search Results - "HOPE, S."

An Overview of PARP Inhibitors for the Treatment of Breast Cancer by Cortesi, Laura, Rugo, Hope S., Jackisch, Christian

“…Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected patients with breast cancer (BC). These BC susceptibility genes encode…”
Get full text

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer by Huppert, Laura A., Gumusay, Ozge, Idossa, Dame, Rugo, Hope S.

“…Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐negative breast cancer is defined by the presence of the estrogen receptor…”
Get full text

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer by Cortes, Javier, Rugo, Hope S., Cescon, David W., Im, Seock-Ah, Yusof, Mastura M., Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H., Perez-Garcia, Jose, Iwata, Hiroji, Masuda, Norikazu, Torregroza Otero, Marco, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhou, Xuan, Karantza, Vassiliki, Pan, Wilbur, Schmid, Peter

“…Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than…”
Get full text

Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual by Giuliano, Armando E., Connolly, James L., Edge, Stephen B., Mittendorf, Elizabeth A., Rugo, Hope S., Solin, Lawrence J., Weaver, Donald L., Winchester, David J., Hortobagyi, Gabriel N.

“…Answer questions and earn CME/CNE The revision of the eighth edition of the primary tumor, lymph node, and metastasis (TNM) classification of the American…”
Get full text

Management of Cancer Cachexia: ASCO Guideline by Roeland, Eric J, Bohlke, Kari, Baracos, Vickie E, Bruera, Eduardo, Del Fabbro, Egidio, Dixon, Suzanne, Fallon, Marie, Herrstedt, Jørn, Lau, Harold, Platek, Mary, Rugo, Hope S, Schnipper, Hester H, Smith, Thomas J, Tan, Winston, Loprinzi, Charles L

“…To provide evidence-based guidance on the clinical management of cancer cachexia in adult patients with advanced cancer. A systematic review of the literature…”
Get full text

Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells by Ruffell, Brian, Chang-Strachan, Debbie, Chan, Vivien, Rosenbusch, Alexander, Ho, Christine M.T., Pryer, Nancy, Daniel, Dylan, Hwang, E. Shelley, Rugo, Hope S., Coussens, Lisa M.

“…Blockade of colony-stimulating factor-1 (CSF-1) limits macrophage infiltration and improves response of mammary carcinomas to chemotherapy. Herein we identify…”
Get full text

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer by André, Fabrice, Ciruelos, Eva, Rubovszky, Gabor, Campone, Mario, Loibl, Sibylle, Rugo, Hope S, Iwata, Hiroji, Conte, Pierfranco, Mayer, Ingrid A, Kaufman, Bella, Yamashita, Toshinari, Lu, Yen-Shen, Inoue, Kenichi, Takahashi, Masato, Pápai, Zsuzsanna, Longin, Anne-Sophie, Mills, David, Wilke, Celine, Hirawat, Samit, Juric, Dejan

“…PIK3CA mutations occur in approximately 40% of patients with hormone receptor–positive breast cancer. A PI3K inhibitor, alpelisib, combined with fulvestrant…”
Get full text

Palbociclib and Letrozole in Advanced Breast Cancer by Finn, Richard S, Martin, Miguel, Rugo, Hope S, Jones, Stephen, Im, Seock-Ah, Gelmon, Karen, Harbeck, Nadia, Lipatov, Oleg N, Walshe, Janice M, Moulder, Stacy, Gauthier, Eric, Lu, Dongrui R, Randolph, Sophia, Diéras, Véronique, Slamon, Dennis J

“…Among women with previously untreated hormone-receptor–positive advanced breast cancer, the addition of the cyclin-dependent kinase inhibitor palbociclib to…”
Get full text

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies by Piha‐Paul, Sarina A., Oh, Do‐Youn, Ueno, Makoto, Malka, David, Chung, Hyun Cheol, Nagrial, Adnan, Kelley, Robin K., Ros, Willeke, Italiano, Antoine, Nakagawa, Kazuhiko, Rugo, Hope S., Braud, Filippo, Varga, Andrea Iolanda, Hansen, Aaron, Wang, Hui, Krishnan, Suba, Norwood, Kevin G., Doi, Toshihiko

“…We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE‐158 (NCT02628067; phase 2) and KEYNOTE‐028…”
Get full text

Achieving Improved Survival Outcomes in Advanced Breast Cancer by Rugo, Hope S

“…Breast cancer is the most common cancer diagnosis in young women. 1 In the United States, the incidence of breast cancer among women under the age of 50 is…”
Get full text

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study by Emens, Leisha A, Molinero, Luciana, Loi, Sherene, Rugo, Hope S, Schneeweiss, Andreas, Diéras, Véronique, Iwata, Hiroji, Barrios, Carlos H, Nechaeva, Marina, Nguyen-Duc, Anh, Chui, Stephen Y, Husain, Amreen, Winer, Eric P, Adams, Sylvia, Schmid, Peter

“…Abstract Background Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of…”
Get full text

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study by Rugo, Hope S, Lerebours, Florence, Ciruelos, Eva, Drullinsky, Pamela, Ruiz-Borrego, Manuel, Neven, Patrick, Park, Yeon Hee, Prat, Aleix, Bachelot, Thomas, Juric, Dejan, Turner, Nicholas, Sophos, Nickolas, Zarate, Juan Pablo, Arce, Christina, Shen, Yu-Ming, Turner, Stuart, Kanakamedala, Hemanth, Hsu, Wei-Chun, Chia, Stephen

“…Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced…”
Get full text

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer by Shastry, Mythili, Jacob, Saya, Rugo, Hope S., Hamilton, Erika

“…Antibody drug conjugates (ADCs) combine the potent cytotoxicity of chemotherapy with the antigen -specific targeted approach of antibodies into one single…”
Get full text

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update by Burstein, Harold J, Somerfield, Mark R, Barton, Debra L, Dorris, Ali, Fallowfield, Lesley J, Jain, Dharamvir, Johnston, Stephen R D, Korde, Larissa A, Litton, Jennifer K, Macrae, Erin R, Peterson, Lindsay L, Vikas, Praveen, Yung, Rachel L, Rugo, Hope S

“…To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. An Expert Panel conducted a…”
Get full text

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial by Frenel, Jean-Sebastien, Le Tourneau, Christophe, O'Neil, Bert, Ott, Patrick A, Piha-Paul, Sarina A, Gomez-Roca, Carlos, van Brummelen, Emilie M J, Rugo, Hope S, Thomas, Shari, Saraf, Sanatan, Rangwala, Reshma, Varga, Andrea

“…Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed…”
Get full text

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study by Ott, Patrick A, Bang, Yung-Jue, Berton-Rigaud, Dominique, Elez, Elena, Pishvaian, Michael J, Rugo, Hope S, Puzanov, Igor, Mehnert, Janice M, Aung, Kyaw L, Lopez, Juanita, Carrigan, Marion, Saraf, Sanatan, Chen, Mei, Soria, Jean-Charles

“…Purpose The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti-programmed death 1…”
Get full text

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial by Schmid, Peter, Rugo, Hope S, Adams, Sylvia, Schneeweiss, Andreas, Barrios, Carlos H, Iwata, Hiroji, Diéras, Véronique, Henschel, Volkmar, Molinero, Luciana, Chui, Stephen Y, Maiya, Vidya, Husain, Amreen, Winer, Eric P, Loi, Sherene, Emens, Leisha A

“…Immunotherapy in combination with chemotherapy has shown promising efficacy across many different tumour types. We report the prespecified second interim…”
Get full text

Risk-Based Screening for Cancer in Patients With Dermatomyositis: Toward a More Individualized Approach by Vaughan, Heidi, Rugo, Hope S, Haemel, Anna

Get more information

Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum by Dent, Rebecca, Rugo, Hope S

“…Molecular analyses interrogating the heterogeneity of TNBC have identified that a substantial proportion of patients harbour defects in DNA repair, driving…”
Get full text

Little Downside by Singer, Lisa, Rugo, Hope S.

Get full text